REGISTER
OCC 2026 | Training HCM Specialists & the Future of Care | Prof. Martin Maron
Prof. Martin Maron discusses the need for dedicated cardiomyopathy training to prepare future HCM specialists. He also reflects on the value of patient education and modern therapies, while looking ahead to earlier CMI use, broader treatment strategies, and combination therapies for HCM.

In OCC 2026 Quest for Truth roundtable, leading experts from China and the United States gather to discuss “Cardiomyopathy: From Misdiagnosis to Precision Medicine”. The session is hosted by Prof. Gang Wu, MD, PhD, Department of Cardiology, Shanghai General Hospital, and co-hosted by Prof. Zeping Qiu, MD, PhD, Department of Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. Quest for Truth is honored to welcome two distinguished guest speakers: Prof. Martin Maron, MD, PhD, Hypertrophic Cardiomyopathy Center and Research Institute, Tufts Medical Center; and Prof. Wei Jin, MD, PhD, Department of Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine.

The roundtable focuses on “Cardiomyopathy: From Misdiagnosis to Precision Medicine”, with in-depth discussions on hypertrophic cardiomyopathy (HCM) diagnosis and management, genetic testing, cardiac myosin inhibitors, real-world clinical experience, patient-centered treatment decisions, HCM Centers of Excellence, specialist training, and future directions in precision cardiovascular care.

Prof. Martin Maron explains that cardiovascular training in the United States includes structured pathways in general cardiology and heart failure, but dedicated subspecialty training in cardiomyopathy is still lacking. He emphasizes that specific cardiomyopathy training programs are needed to prepare the next generation of specialists.

Prof. Martin Maron also reflects on the most meaningful parts of his career. He highlights the satisfaction of seeing patients improve with modern HCM therapies, as well as the value of educating patients so they can better understand their disease and feel more confident in managing it.

Looking ahead, They suggest that the next phase of HCM care may involve earlier intervention with cardiac myosin inhibitors, broader treatment for less symptomatic patients, and the development of combination therapies targeting different disease pathways. These advances may help improve outcomes across both obstructive and non-obstructive HCM.

0
0
Loading